Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013 | Zendy

Hélio S. Sader | Zendy; Mariana Castanheira | Zendy; Rodrigo E. Mendes | Zendy; Robert K. Flamm | Zendy; David J. Farrell | Zendy; Ronald N. Jones | Zendy

Open Access

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

Author(s) -

Hélio S. Sader,

Mariana Castanheira,

Rodrigo E. Mendes,

Robert K. Flamm,

David J. Farrell,

Ronald N. Jones

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.05024-14

Subject(s) - ceftazidime/avibactam , pseudomonas aeruginosa , ceftazidime , microbiology and biotechnology , avibactam , medicine , multiple drug resistance , antibiotics , biology , bacteria , genetics

Pseudomonas aeruginosa isolates (n = 3,902) from 75 U.S. medical centers were tested against ceftazidime-avibactam and comparator agents by the reference broth microdilution method. Overall, 96.9% of the strains were susceptible (MIC, ≤8 μg/ml) to ceftazidime-avibactam, while the rates of susceptibility for ceftazidime, meropenem, and piperacillin-tazobactam were 83.8, 81.9, and 78.5%, respectively. Multidrug-resistant and extensively drug-resistant phenotypes were observed in 14.9 and 8.7% of the strains, respectively, and 81.0 and 73.7% of the strains were susceptible to ceftazidime-avibactam, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research